162 related articles for article (PubMed ID: 36982681)
1. Pharmacogenetics of the Primary and Metastatic Osteosarcoma: Gene Expression Profile Associated with Outcome.
Trujillo-Paolillo A; Tesser-Gamba F; Seixas Alves MT; Filho RJG; Oliveira R; Petrilli AS; Toledo SRC
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982681
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetic analysis of high-dose methotrexate treatment in children with osteosarcoma.
Hegyi M; Arany A; Semsei AF; Csordas K; Eipel O; Gezsi A; Kutszegi N; Csoka M; Muller J; Erdelyi DJ; Antal P; Szalai C; Kovacs GT
Oncotarget; 2017 Feb; 8(6):9388-9398. PubMed ID: 27566582
[TBL] [Abstract][Full Text] [Related]
3. MAPK pathways regulation by DUSP1 in the development of osteosarcoma: Potential markers and therapeutic targets.
Lopes LJS; Tesser-Gamba F; Petrilli AS; de Seixas Alves MT; Garcia-Filho RJ; Toledo SRC
Mol Carcinog; 2017 Jun; 56(6):1630-1641. PubMed ID: 28112450
[TBL] [Abstract][Full Text] [Related]
4. S-adenosylmethionine blocks osteosarcoma cells proliferation and invasion in vitro and tumor metastasis in vivo: therapeutic and diagnostic clinical applications.
Parashar S; Cheishvili D; Arakelian A; Hussain Z; Tanvir I; Khan HA; Szyf M; Rabbani SA
Cancer Med; 2015 May; 4(5):732-44. PubMed ID: 25619880
[TBL] [Abstract][Full Text] [Related]
5. Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients.
Caronia D; Patiño-García A; Milne RL; Zalacain-Díez M; Pita G; Alonso MR; Moreno LT; Sierrasesumaga-Ariznabarreta L; Benítez J; González-Neira A
Pharmacogenomics J; 2009 Oct; 9(5):347-53. PubMed ID: 19434073
[TBL] [Abstract][Full Text] [Related]
6. CYP genes in osteosarcoma: Their role in tumorigenesis, pulmonary metastatic microenvironment and treatment response.
Trujillo-Paolillo A; Tesser-Gamba F; Petrilli AS; de Seixas Alves MT; Garcia Filho RJ; de Oliveira R; de Toledo SRC
Oncotarget; 2017 Jun; 8(24):38530-38540. PubMed ID: 28404946
[TBL] [Abstract][Full Text] [Related]
7. MiR-9 is overexpressed in spontaneous canine osteosarcoma and promotes a metastatic phenotype including invasion and migration in osteoblasts and osteosarcoma cell lines.
Fenger JM; Roberts RD; Iwenofu OH; Bear MD; Zhang X; Couto JI; Modiano JF; Kisseberth WC; London CA
BMC Cancer; 2016 Oct; 16(1):784. PubMed ID: 27724924
[TBL] [Abstract][Full Text] [Related]
8. Identification of differentially expressed genes in the development of osteosarcoma using RNA-seq.
Yang Y; Zhang Y; Qu X; Xia J; Li D; Li X; Wang Y; He Z; Li S; Zhou Y; Xie L; Yang Z
Oncotarget; 2016 Dec; 7(52):87194-87205. PubMed ID: 27888627
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA34a is associated with chemotherapy resistance, metastasis, recurrence, survival, and prognosis in patient with osteosarcoma.
Lian H; Zhou Y; Sun Z; Liu K
Medicine (Baltimore); 2022 Sep; 101(38):e30722. PubMed ID: 36197268
[TBL] [Abstract][Full Text] [Related]
10. Long Non-coding RNAs in Cisplatin Resistance in Osteosarcoma.
Ferretti VA; León IE
Curr Treat Options Oncol; 2021 Mar; 22(5):41. PubMed ID: 33745006
[TBL] [Abstract][Full Text] [Related]
11. Expression of 11β-hydroxysteroid dehydrogenase enzymes in human osteosarcoma: potential role in pathogenesis and as targets for treatments.
Patel P; Hardy R; Sumathi V; Bartle G; Kindblom LG; Grimer R; Bujalska I; Stewart PM; Rabbitt E; Gittoes NJ; Cooper MS
Endocr Relat Cancer; 2012 Aug; 19(4):589-98. PubMed ID: 22719058
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-184 Modulates Doxorubicin Resistance in Osteosarcoma Cells by Targeting BCL2L1.
Lin BC; Huang D; Yu CQ; Mou Y; Liu YH; Zhang DW; Shi FJ
Med Sci Monit; 2016 May; 22():1761-5. PubMed ID: 27222034
[TBL] [Abstract][Full Text] [Related]
13. Clinical impact of the methotrexate resistance-associated genes C-MYC and dihydrofolate reductase (DHFR) in high-grade osteosarcoma.
Scionti I; Michelacci F; Pasello M; Hattinger CM; Alberghini M; Manara MC; Bacci G; Ferrari S; Scotlandi K; Picci P; Serra M
Ann Oncol; 2008 Aug; 19(8):1500-1508. PubMed ID: 18385200
[TBL] [Abstract][Full Text] [Related]
14. MiR-34c inhibits osteosarcoma metastasis and chemoresistance.
Xu M; Jin H; Xu CX; Bi WZ; Wang Y
Med Oncol; 2014 Jun; 31(6):972. PubMed ID: 24802328
[TBL] [Abstract][Full Text] [Related]
15. Emerging next-generation sequencing-based discoveries for targeted osteosarcoma therapy.
Zhao J; Dean DC; Hornicek FJ; Yu X; Duan Z
Cancer Lett; 2020 Apr; 474():158-167. PubMed ID: 31987920
[TBL] [Abstract][Full Text] [Related]
16. Gene expression profiling of canine osteosarcoma reveals genes associated with short and long survival times.
Selvarajah GT; Kirpensteijn J; van Wolferen ME; Rao NA; Fieten H; Mol JA
Mol Cancer; 2009 Sep; 8():72. PubMed ID: 19735553
[TBL] [Abstract][Full Text] [Related]
17. MAPK7 and MAP2K4 as prognostic markers in osteosarcoma.
Tesser-Gamba F; Petrilli AS; de Seixas Alves MT; Filho RJ; Juliano Y; Toledo SR
Hum Pathol; 2012 Jul; 43(7):994-1002. PubMed ID: 22154052
[TBL] [Abstract][Full Text] [Related]
18. The role of pharmacogenetics in the treatment of osteosarcoma.
Vos HI; Coenen MJ; Guchelaar HJ; Te Loo DM
Drug Discov Today; 2016 Nov; 21(11):1775-1786. PubMed ID: 27352631
[TBL] [Abstract][Full Text] [Related]
19. Combined analysis of DNA methylation and gene expression profiles of osteosarcoma identified several prognosis signatures.
Tian W; Li Y; Zhang J; Li J; Gao J
Gene; 2018 Apr; 650():7-14. PubMed ID: 29407229
[TBL] [Abstract][Full Text] [Related]
20. The pharmacogenomics of osteosarcoma.
Serra M; Hattinger CM
Pharmacogenomics J; 2017 Jan; 17(1):11-20. PubMed ID: 27241064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
